ADMA Biologics Inc - Asset Resilience Ratio
ADMA Biologics Inc (ADMA) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how ADMA Biologics Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of ADMA Biologics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down ADMA Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ADMA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ADMA Biologics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ADMA Biologics Inc Industry Peers by Asset Resilience Ratio
Compare ADMA Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for ADMA Biologics Inc (2012–2017)
The table below shows the annual Asset Resilience Ratio data for ADMA Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 1.39% | $1.50 Million | $108.02 Million | -21.37pp |
| 2016-12-31 | 22.76% | $5.39 Million | $23.69 Million | -4.10pp |
| 2015-12-31 | 26.85% | $6.37 Million | $23.71 Million | +9.77pp |
| 2014-12-31 | 17.09% | $4.65 Million | $27.23 Million | +7.91pp |
| 2013-12-31 | 9.18% | $2.94 Million | $31.98 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $15.56 Million | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more